19 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2030. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
8
Ending by 2030
Oct 2030
Next term end
4
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2037 · High confidence
Also notable
Ends Oct 2030 · High confidence
Also notable
Ends Sep 2034 · High confidence
Methods of Treating Eosinophilic Esophagitis
US 11,684,571
Cited by 13 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Orally Administered Corticosteroid Compositions
US 11,246,828
Cited by 17 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Corticosteroid Containing Orally Disintegrating Tablet Compositions for Eosinophilic Esophagitis
US 11,260,061
Cited by 14 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 27, 2026The maintenance fee for Methods of Treating Eosinophilic Esophagitis (US 11,684,571) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
- 1 fee due May 12, 2027The maintenance fee for Corticosteroid Containing Orally Disintegrating Tablet Compositions for Eosinophilic Esophagitis (US 10,471,071) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 1 fee due Aug 13, 2027The maintenance fee for Methods of Treating Eosinophilic Esophagitis (US 11,896,710) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
- 1 fee due Oct 28, 2027The maintenance fee for Orally Administered Corticosteroid Compositions (US 10,632,069) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Orally Administered Corticosteroid Compositions | 8 in force | to Dec 2030 |
| Methods of Treating Eosinophilic Esophagitis | 5 in force | to Aug 2037 |
| Corticosteroid Containing Orally Disintegrating Tablet Compositions for Eosinophilic Esophagitis | 5 in force | to Sep 2034 |
| Methods of Treating Eosinophilic Esophagitis and Reducing Candidiasis | 1 in force | to Aug 2043 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,387,167 | Orally Administered Corticosteroid Compositions In force · High confidence | In force | High confidence | |
| US 9,486,407 | Orally Administered Corticosteroid Compositions In force · High confidence | In force | High confidence | |
| US 9,849,084 | Orally Administered Corticosteroid Compositions In force · High confidence | In force | High confidence | |
| US 10,632,069 | Orally Administered Corticosteroid Compositions In force · High confidence | In force | High confidence | |
| US 11,246,828 | Orally Administered Corticosteroid Compositions In force · High confidence | In force | High confidence | |
| US 11,266,598 | Orally Administered Corticosteroid Compositions In force · High confidence | In force | High confidence | |
| US 12,290,598 | Orally Administered Corticosteroid Compositions In force · High confidence | In force | High confidence | |
| US 8,771,729 | Orally Administered Corticosteroid Compositions In force · High confidence | In force | High confidence | |
| US 10,471,071 | Corticosteroid Containing Orally Disintegrating Tablet Compositions for Eosinophilic Esophagitis In force · High confidence | In force | High confidence | |
| US 11,166,961 | Corticosteroid Containing Orally Disintegrating Tablet Compositions for Eosinophilic Esophagitis In force · High confidence | In force | High confidence |
Also on record, not counted in the 19: 1 patent ended · 7 applications pending · 5 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.